Core Viewpoint - The company has received approval from the National Medical Products Administration for the registration of aluminum magnesium carbonate chewable tablets, which enhances its product pipeline and supports sustainable development [1][4]. Drug Basic Information - Drug Name: Aluminum Magnesium Carbonate Chewable Tablets - Dosage Form: Tablet - Specification: 0.5g - Registration Classification: Class 4 Chemical Drug - Approval Number: Guo Yao Zhun Zi H20263134 - License Holder: Hunan Qianjin Xiangjiang Pharmaceutical Co., Ltd. - Approval Conclusion: The drug meets registration requirements and is classified as a Class A over-the-counter medication [1]. Drug Efficacy and Market Potential - Aluminum magnesium carbonate chewable tablets are a first-line medication for the digestive system, providing antacid, bile acid neutralization, and mucosal protection, suitable for treating various gastric diseases including acute and chronic gastritis, gastric and duodenal ulcers, and gastroesophageal reflux disease [2]. - The product is projected to have a total sales volume of 990 million yuan in the domestic medical and retail markets by 2024 [2]. R&D Investment - As of the announcement date, the cumulative R&D investment in aluminum magnesium carbonate chewable tablets by Qianjin Xiangjiang Pharmaceutical is 1.0047 million yuan [3]. Impact on the Company - The approval of aluminum magnesium carbonate chewable tablets is seen as a significant step in enhancing the company's product offerings, contributing positively to its sustainable growth [4].

Core Viewpoint - Qianjin Pharmaceutical announced that its subsidiary, Hunan Qianjin Xiangjiang Pharmaceutical, has received approval from the National Medical Products Administration for the registration certificate of aluminum magnesium carbonate chewable tablets, indicating successful consistency evaluation for treating upper gastrointestinal diseases such as gastritis and ulcers [1] Group 1 - The approved product is aluminum magnesium carbonate chewable tablets with a specification of 0.5g [1] - The expected domestic sales for 2024 are projected to be 990 million yuan [1] - The total research and development investment for the product amounts to 1.0047 million yuan [1]

Group 1 - The company Qianjin Pharmaceutical announced that its subsidiary Hunan Qianjin Xiangjiang Pharmaceutical has received the drug registration certificate for Aluminum Magnesium Carbonate Chewable Tablets from the National Medical Products Administration [1] Group 2 - The international gold price has surpassed $5000, marking a 280% increase over the past seven years, with experts suggesting that the key factors influencing this trend include the US dollar, the international monetary system, interest rate cuts, and technological revolutions [1]

证券代码：600479 证券简称：千金药业 公告编号：2026-004 株洲千金药业股份有限公司 关于子公司获得药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，株洲千金药业股份有限公司（以下简称"公司"）下属子公司湖南千 金湘江药业股份有限公司（以下简称"千金湘江药业"）收到国家药品监督管理 局核准签发的铝碳酸镁咀嚼片《药品注册证书》。现将相关情况公告如下： 一、药品基本信息 药品名称：铝碳酸镁咀嚼片 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品 符合药品注册的有关要求，批准注册，发给药品注册证书。同意本品按甲类非处 方药管理。质量标准、说明书、标签及生产工艺照所附执行。药品生产企业应当 符合药品生产质量管理规范要求方可生产销售。 二、药品其他相关信息 铝碳酸镁咀嚼片为消化系统一线用药，具有抗酸、抗胆汁、保护黏膜的功效， 三效合一整体治疗上消化道疾病。该产品适用于广泛治疗多种胃部疾病：1.急、 慢性胃炎；2.胃、十二指肠溃疡；3.反流性食管炎；4.与胃酸有关的胃部不适症 状，如胃 ...

Core Viewpoint - Qianjin Pharmaceutical's subsidiary, Qianjin Xiangjiang Pharmaceutical, has received approval from the National Medical Products Administration for the registration of aluminum magnesium carbonate chewable tablets, enhancing the company's product pipeline and supporting sustainable development [1] Group 1 - The approved drug is a first-line medication for the digestive system, providing antacid, bile acid neutralization, and mucosal protection effects [1] - The approval of the drug registration certificate is equivalent to passing the consistency evaluation, which is a significant milestone for the company [1] Group 2 - The production and sales of the drug are subject to national policies and market environment changes, indicating a high level of uncertainty [1]

Core Viewpoint - The company, Zhuzhou Qianjin Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for its product, Bu Xue Yi Mu Wan, to be classified as the first secondary protected traditional Chinese medicine variety, enhancing its market competitiveness in postpartum recovery medication [1]. Group 1 - The approval of Bu Xue Yi Mu Wan as a secondary protected variety strengthens the company's intellectual property protection [1]. - Bu Xue Yi Mu Wan is recognized as a national basic drug, a Class A medical insurance variety, and an exclusive product, included in various clinical application guidelines and textbooks [1]. - The product is indicated for conditions related to postpartum abdominal pain due to deficiency of both qi and blood, as well as blood stasis [1]. Group 2 - The company anticipates that this approval will positively impact its production and operations [1]. - The sales performance of the drug may be influenced by national policies and market environment changes, indicating a level of uncertainty [2].

Group 1: Profit Forecasts - Limin Co. expects a net profit of 465 million to 500 million yuan for 2025, representing a year-on-year increase of 471.55% to 514.57% [1] - Guohui Energy anticipates a net profit of 1.32 billion to 1.47 billion yuan for 2025, reflecting a decline of 50.03% to 55.13% year-on-year [2] - Jiajia Yue forecasts a net profit of 198 million to 228 million yuan for 2025, indicating a growth of 50.06% to 72.79% year-on-year [3] - Xianghe Industry projects a net profit of 120 million to 148 million yuan for 2025, with an expected increase of 59.17% to 96.31% year-on-year [4] - Aojie Technology predicts a net profit of 90 million to 120 million yuan for 2025, showing a growth of 228.34% to 337.79% year-on-year [14] - Shanghai Electric expects a net profit of 1.1 billion to 1.32 billion yuan for 2025, representing an increase of approximately 47% to 76% year-on-year [15] - Tianfu Communication anticipates a net profit of 1.881 billion to 2.15 billion yuan for 2025, reflecting a growth of 40% to 60% year-on-year [16] - Yichang Technology forecasts a net profit of 150 million to 225 million yuan for 2025, indicating a year-on-year increase of 58% to 138% [29] - Shanghai Yizhong expects a net profit of 60 million to 70 million yuan for 2025, representing a significant increase of 760.18% to 903.54% year-on-year [41] Group 2: Loss Forecasts - Kexin Electromechanical anticipates a net profit of 55 million to 70 million yuan for 2025, reflecting a decline of 58.65% to 67.51% year-on-year [11][12] - Kexin Technology expects a net loss of 900 million to 1.2 billion yuan for 2025, which is an increase in loss of 78.67% to 84% year-on-year [10] - Tianyang New Materials forecasts a net loss of 250 million to 180 million yuan for 2025, compared to a loss of 213 million yuan in the previous year [20] - Bo Rui Data anticipates a net loss of 90 million to 100 million yuan for 2025, which is an increase in loss of 15.17 million to 25.17 million yuan year-on-year [19] - Xinlian Integrated expects a net loss of 577 million yuan for 2025, which is a reduction in loss of approximately 40.02% compared to the previous year [40] - Fangshilong forecasts a net loss of 4 million to 6 million yuan for 2025 [30] Group 3: Strategic Developments - Lianlong signed a strategic framework agreement with Runyinglian to enhance the reliability and efficiency of the lubricant additive supply chain in China and the Asia-Pacific region [7] - Han Jian Heshan is planning to acquire a 52.51% stake in Liaoning Xingfu New Materials Co., Ltd., with stock suspension expected for up to 9 trading days [13] - Kai Zhong Precision plans to invest 116 million yuan in a technical transformation and expansion project to meet future capacity demands [34] - Tianfu Communication is expected to engage in clinical trials for its ABA001 injection, which has received approval from the National Medical Products Administration [17]

Core Viewpoint - Qianjin Pharmaceutical (600479.SH) has received approval from the National Medical Products Administration for its product, Bu Xue Yi Mu Wan, to be the first Chinese medicine classified as a secondary protected variety, enhancing its intellectual property protection and market competitiveness in postpartum recovery medication [1] Group 1 - The National Medical Products Administration published the announcement on January 20, 2026, approving Bu Xue Yi Mu Wan as the first secondary protected variety of traditional Chinese medicine [1] - Bu Xue Yi Mu Wan is recognized as a national basic drug, a Class A medical insurance product, and an exclusive product, included in various clinical application guidelines and textbooks [1] - The product is indicated for conditions related to postpartum abdominal pain due to deficiency of both qi and blood, as well as blood stasis [1] Group 2 - The approval strengthens the company's intellectual property protection for its products, which is expected to positively impact its production and operations [1] - The recognition of Bu Xue Yi Mu Wan is anticipated to enhance the company's competitiveness in the postpartum recovery medication market [1]

Core Viewpoint - Qianjin Pharmaceutical (600479.SH) has received approval from the National Medical Products Administration for its product, Bu Xue Yi Mu Wan, to be the first Chinese medicine to be classified as a secondary protected variety, enhancing the company's intellectual property protection and market competitiveness in postpartum recovery medication [1] Group 1 - The National Medical Products Administration published the announcement on January 20, 2026, approving Bu Xue Yi Mu Wan as the first secondary protected variety of traditional Chinese medicine [1] - Bu Xue Yi Mu Wan is recognized as a national basic drug, a Class A medical insurance product, and an exclusive product, and is included in several clinical application guidelines and textbooks [1] - The product is indicated for conditions related to postpartum abdominal pain due to deficiency of both qi and blood, as well as blood stasis [1] Group 2 - The approval of Bu Xue Yi Mu Wan is expected to positively impact the company's production and operations by strengthening its market position in the postpartum recovery medication sector [1]

证券代码：600479 证券简称：千金药业 公告编号：2026-003 株洲千金药业股份有限公司 关于补血益母丸获批国家中药保护品种的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 2026 年 1 月 20 日，国家药品监督管理局网站发布了《中药保护品种公告（第 34 号）》（2026 年第 11 号），国家药品监督管理局批准株洲千金药业股份有限 公司（以下简称"公司"）的补血益母丸为首家中药二级保护品种，具体内容如 下： | 药品品种 | 保护期限 | 保护品种编号 | 生产企业 | | --- | --- | --- | --- | | 补血益母丸 | 自公告日起七年 | ZYB2072026009 | 株洲千金药业股份有限 公司 | 补血益母丸为国基药品种、医保甲类品种、独家品种，被《国家基本药物临 床应用指南（中成药）2018 年版》、《中成药临床应用指南（第二版 妇科疾病 分册）》、《中医妇科学（全国中医药高等教育十四五规划教材）》等指南及教 科书收录推荐。该产品适用于气血两虚兼血瘀证产后腹痛。 本次公司补血 ...